司來吉蘭
Selegiline
L-deprenyl
別名: Selgian · Anipryl · L-deprenyl · selegiline hydrochloride
由 VetSheet 獸醫團隊審訂更新於 2026年4月5日本內容以實證獸醫文獻為本
劑量為合格獸醫專業人員的臨床參考。請務必對照最新仿單及個別病患確認。
各物種劑量
🌎 NA — North America🌍 EU — Europe
狗
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Behavioural disorders and cognitive dysfunction | 0.5-1 mg/kg | PO | q24h | minimum of 2 months | 🌍 EU |
- Behavioural disorders and cognitive dysfunction: Treatment can be stopped suddenly without gradual dose reduction.
貓
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Cognitive decline in older cats | 1 mg/kg | PO | q24h | Not specified | 🌍 EU |
- Cognitive decline in older cats: Treatment can be stopped suddenly without gradual dose reduction.
劑量為合格獸醫專業人員的臨床參考。請務必對照最新仿單及個別病患確認。
概覽
司來吉蘭 (L-deprenyl) 是一種單胺氧化酶抑制劑，被核准用於治療純情緒引起的行為障礙，如憂鬱和焦慮。它常與行為療法結合，用於治療過度活躍、分離焦慮、廣泛性恐懼症和不合群行為。
這些情緒障礙的特徵通常包括飲食、飲水、自我刺激行為、睡眠、探索行為的改變，以及與恐懼/刺激相關的攻擊行為和軀體障礙（如心搏過速、情緒性排尿）。
臨床提示： 司來吉蘭非常適用於犬認知功能障礙 (CCD)，特別是伴隨焦慮或社交退縮時，也可用於治療高齡貓的認知衰退跡象。其獨特之處在於可以突然停藥，無需逐漸減量。
作用機轉
Selegiline modifies the concentration of monoaminergic neurotransmitters, especially phenylethylamine and dopamine, by selectively inhibiting the activity of Type-B monoamine oxidase (MAO-B), the enzyme that normally breaks down these chemicals.
MAO-B inhibition → decreased breakdown of dopamine → increased dopamine concentrations in the CNS. It also appears to possess neuroprotective properties.
安全性與警告
禁忌症
- Known sensitivity to selegiline
- Lactating bitches (acts on prolactin secretion)
- Pregnant bitches
不良反應
- No specific adverse reactions are listed in the monograph
- Clinical Pearl: May occasionally cause mild gastrointestinal upset, restlessness, or lethargy
注意事項
Normal safety and handling precautions should be observed.
Warning: Do not use in pregnant or lactating bitches due to its effects on prolactin secretion. Strict washout periods are required when switching to or from other psychoactive medications (e.g., TCAs, SSRIs).
藥物交互作用
Should not be administered concurrently or within 24 hours before/after use
Contraindicated concurrent use
Contraindicated concurrent use
Potential MAOI interaction; contraindicated
Contraindicated concurrent use
Potentiates the effect of morphine
Potential interaction exists
Potential interaction exists
Potential interaction exists
Do not use selegiline for at least 2-3 weeks after TCA use
Do not use selegiline for at least 6 weeks after long-term fluoxetine use
監測
- Improvement in behavioural signs (anxiety, phobias, social withdrawal)
- Improvement in cognitive function (disorientation, sleep-wake cycle alterations)
- Adverse drug interactions if other medications are introduced
過量
No specific overdose information is provided in the monograph.
Clinical Pearl: Overdoses of MAOIs can lead to signs of serotonin syndrome or excessive dopaminergic stimulation, including hyperthermia, tachycardia, tremors, and agitation. Treatment is supportive.
可用產品
劑型
- 4 mg oral tablet
- 10 mg oral tablet
獸醫用
- 4 mg tablets
- 10 mg tablets
各地核准狀態
Approved for canine cognitive dysfunction and pituitary-dependent hyperadrenocorticism in the US.
POM-V classification.
POM-V classification.
暫無法規資料: 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
儲存與穩定性
Normal precautions should be observed. Store in a cool, dry place away from direct sunlight.
飼主須知
司來吉蘭用於幫助控制高齡寵物的行為問題，如焦慮、恐懼症和認知功能障礙（失智症）。
- 給藥方式： 請嚴格按照獸醫的指示給藥。通常需要數週（至少2個月）才能看到完整療效。
- 停藥： 與其他一些行為藥物不同，司來吉蘭可以突然停藥，不需要慢慢減少劑量。
- 重要警告： 請告知獸醫您的寵物正在使用的所有藥物、保健品或除蚤項圈（特別是含有雙甲脒 amitraz 的產品），因為司來吉蘭可能與許多其他藥物產生嚴重的交互作用。
- 懷孕： 請勿用於懷孕或哺乳期的動物。
VetSheet 藥物參考供合格獸醫專業人員作臨床決策輔助之用，不能取代專業判斷或廠商最新仿單。